The latest market report published by Credence Research, Inc. “Global Diagnostic Testing for STD’s Market – Growth, Future Prospects, Competitive Analysis, 2018 – 2026,” the global diagnostic testing for STD’s market is expected to reach was valued at US$ 19,716.9 Mn in 2017, and is expected to reach US$ 42,329.1 Mn by 2026, expanding at a CAGR of 8.9% from 2018 to 2026.
According to the statistics provided by World Health Organization (WHO), each year there are approximately 357 million new infection cases of 1 in 4 sexually transmitted infections pertaining to gonorrhea, syphilis, chlamydia, and trichomoniaisis. It is reported that more than 30 different types of pathogens are sexually transmitted of which only bacterial infections are curable. The viral infections are incurable with only symptomatic relief through effective treatment protocols. Rising incidence of bacterial resistance to antibiotics results in huge demand for early screening of sexually transmitted diseases.
At present chlamydia and syphilis together are leading the type segment for diagnostic testing for STD’s market. The key factors responsible for their dominance are higher indulgence of unsafe sex with multiple partners throughout the globe and increasing sexual contact with anal and oral regions. HIV infection testing is witnessing impressive growth due to availability of highly sensitive and effective molecular diagnostic kits for PCR and ELISA techniques. Increasing campaigning by governmental and non-governmental agencies resulting in early screening for HIV infection.
In the current scenario laboratory testing are reigning the location segment for diagnostic testing for STD’s market. The key parameters responsible for its excellent growth are availability of skilled workforce and establishment of new diagnostic laboratories due to financial pumping from government healthcare agencies. Point of care testing will register huge growth during the forecast period owing to availability of latest molecular diagnostic kits with improved ergonomic designs, portability, and quick turnaround time related to diagnosis.
According to Center for Disease Control and Prevention (CDC) in 2017, approximately 2.3 million people are suffering with sexually transmitted disease in the United States. Factors responsible for the dominance of North America are existence of well-developed healthcare infrastructure and domicile of key players. In Europe the market growth is determined by the supportive regulatory environment provided by European Medical Agency favoring the growth of STD’s diagnostic kits. There has been rampant increase in the spread of STD’s throughout the European Union region on account of the recent refugee influx from the Levant region. Asia Pacific is set to register impressive growth during the forecast period on account of rising prevalence of sexually transmitted disease and proactive government initiative in establishing diagnostic centers to curb the spread and fatality of STD’s.
Browse the full report Diagnostic Testing for STD’s Market – Growth, Future Prospects, Competitive Analysis, 2018 – 2026 report at https://www.credenceresearch.com/report/diagnostic-testing-for-stds-market
Archrivals competing in the diagnostic testing for STD’s market are Abbott Laboratories, Inc., Bio-Rad Laboratories, Inc., bioMerieux, Danaher Corporation, Diasorin S.p.A, F.Hoffman La-Roche Ltd., Hologic, Inc., MedMira, Inc., Qiagen, Inc., and Siemens Healthcare AG.
Key Market Movements:
- Rising incidence rate of sexually transmitted disease throughout the globe
- Technological adevanmcent in the molecular diagnostic testing kits used for screening of sexually transmitted diseases
- Supportive regulatory scenario favoring market growth and increasing public health awareness resulting in early screening